These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

515 related items for PubMed ID: 33347814

  • 1. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.
    Morice PM, Leary A, Dolladille C, Chrétien B, Poulain L, González-Martín A, Moore K, O'Reilly EM, Ray-Coquard I, Alexandre J.
    Lancet Haematol; 2021 Feb; 8(2):e122-e134. PubMed ID: 33347814
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study.
    Myers KC, Furutani E, Weller E, Siegele B, Galvin A, Arsenault V, Alter BP, Boulad F, Bueso-Ramos C, Burroughs L, Castillo P, Connelly J, Davies SM, DiNardo CD, Hanif I, Ho RH, Karras N, Manalang M, McReynolds LJ, Nakano TA, Nalepa G, Norkin M, Oberley MJ, Orgel E, Pastore YD, Rosenthal J, Walkovich K, Larson J, Malsch M, Elghetany MT, Fleming MD, Shimamura A.
    Lancet Haematol; 2020 Mar; 7(3):e238-e246. PubMed ID: 31879230
    [Abstract] [Full Text] [Related]

  • 4. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
    Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM.
    Lancet Haematol; 2019 Sep; 6(9):e480-e488. PubMed ID: 31400961
    [Abstract] [Full Text] [Related]

  • 5. PARP inhibitors-understanding the risk of myelodysplastic syndrome and acute myeloid leukaemia.
    Tinker AV.
    Lancet Haematol; 2021 Feb; 8(2):e97-e99. PubMed ID: 33347815
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
    Issa JJ, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, Daver N, Chung W, Naim S, Taverna P, Oganesian A, Hao Y, Lowder JN, Azab M, Kantarjian H.
    Lancet Oncol; 2015 Sep; 16(9):1099-1110. PubMed ID: 26296954
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Arterial hypertension associated with PARPi: A meta-analysis of 41 placebo randomized controlled trials combined with a World Health Organization's pharmacovigilance study.
    Blaize C, Surtouque E, Font J, Dolladille C, Postel-Vinay S, Da Silva A, Alexandre J, Morice PM.
    Fundam Clin Pharmacol; 2024 Aug; 38(4):610-629. PubMed ID: 38268495
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
    DiNardo CD, Daver N, Jabbour E, Kadia T, Borthakur G, Konopleva M, Pemmaraju N, Yang H, Pierce S, Wierda W, Bueso-Ramos C, Patel KP, Cortes JE, Ravandi F, Kantarjian HM, Garcia-Manero G.
    Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
    [Abstract] [Full Text] [Related]

  • 12. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.
    Sallman DA, Kerre T, Havelange V, Poiré X, Lewalle P, Wang ES, Brayer JB, Davila ML, Moors I, Machiels JP, Awada A, Alcantar-Orozco EM, Borissova R, Braun N, Dheur MS, Gilham DE, Lonez C, Lehmann FF, Flament A.
    Lancet Haematol; 2023 Mar; 10(3):e191-e202. PubMed ID: 36764323
    [Abstract] [Full Text] [Related]

  • 13. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
    Mittelman M, Platzbecker U, Afanasyev B, Grosicki S, Wong RSM, Anagnostopoulos A, Brenner B, Denzlinger C, Rossi G, Nagler A, Garcia-Delgado R, Portella MSO, Zhu Z, Selleslag D.
    Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
    [Abstract] [Full Text] [Related]

  • 14. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
    Cortes J, Perl AE, Döhner H, Kantarjian H, Martinelli G, Kovacsovics T, Rousselot P, Steffen B, Dombret H, Estey E, Strickland S, Altman JK, Baldus CD, Burnett A, Krämer A, Russell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M.
    Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
    [Abstract] [Full Text] [Related]

  • 15.
    LeBlanc EL, Patnode CD, Webber EM, Redmond N, Rushkin M, O’Connor EA.
    ; 2018 09. PubMed ID: 30354042
    [Abstract] [Full Text] [Related]

  • 16. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
    Oliva EN, Alati C, Santini V, Poloni A, Molteni A, Niscola P, Salvi F, Sanpaolo G, Balleari E, Germing U, Fenaux P, Stamatoullas A, Palumbo GA, Salutari P, Impera S, Avanzini P, Cortelezzi A, Liberati AM, Carluccio P, Buccisano F, Voso MT, Mancini S, Kulasekararaj A, Morabito F, Bocchia M, Cufari P, Spiriti MA, Santacaterina I, D'Errigo MG, Bova I, Zini G, Latagliata R.
    Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
    [Abstract] [Full Text] [Related]

  • 17. Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial.
    Taylor J, Mi X, Penson AV, Paffenholz SV, Alvarez K, Sigler A, Chung SS, Rampal RK, Park JH, Stein EM, Tallman MS, Sen F, Gönen M, Abdel-Wahab O, Klimek VM.
    Lancet Haematol; 2020 Aug; 7(8):e566-e574. PubMed ID: 32735836
    [Abstract] [Full Text] [Related]

  • 18. Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials.
    Nitecki R, Melamed A, Gockley AA, Floyd J, Krause KJ, Coleman RL, Matulonis UA, Giordano SH, Lu KH, Rauh-Hain JA.
    Gynecol Oncol; 2021 Jun; 161(3):653-659. PubMed ID: 33736856
    [Abstract] [Full Text] [Related]

  • 19. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
    Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, Dinner SN, Pigneux A, Montesinos P, Wang ES, Seiter KP, Wei AH, De Botton S, Arnan M, Donnellan W, Schwarer AP, Récher C, Jonas BA, Ferrell PB, Marzac C, Kelly P, Sweeney J, Forsyth S, Guichard SM, Brevard J, Henrick P, Mohamed H, Cortes JE.
    Lancet Haematol; 2023 Jan; 10(1):e46-e58. PubMed ID: 36370742
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.
    Beguin Y, Selleslag D, Meers S, Graux C, Bries G, Deeren D, Vrelust I, Ravoet C, Theunissen K, Voelter V, Potier H, Trullemans F, Noens L, Mineur P.
    Acta Clin Belg; 2015 Feb; 70(1):34-43. PubMed ID: 25444072
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.